🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,046 results for “infusion” Clear

  1. Continuos epidural infusion

    Hospital Authority, Hong Kong

    Analgesia, Epidural

    approved other active

    1 trial
  2. Control: Femoral perineural local anesthetic infusion

    Summit Therapeutics

    Postoperative Pain Following Knee Arthroplasty

    approved small molecule completed

    1 trial
  3. Doxorubicin Accord 2 mg/ml koncentrat till infusionsvätska, lösning, Paclitaxel Accord 6 mg/ml koncentrat till infusionsvätska, lösning, Docetaxel Ebewe 10 mg/ml koncentrat till infusionsvätska, lösning, Epirubicin Accord 2 mg/ml injektions-/infusionsvätska, lösning, Sendoxan pulver till injektionsvätska, lösning

    The George Institute

    Breast cancer female NOS

    approved small molecule active

    1 trial
  4. Elaprase for intravenous (IV) infusion

    Takeda

    Hunter Syndrome

    approved small molecule completed

    1 trial
  5. Elaprase for intravenous (IV) infusion

    Shire

    Hunter Syndrome

    approved small molecule completed

    1 trial
  6. HYDROXYCHLOROQUINE , ABATACEPT , AZATHIOPRINE , SULFASALAZINE , METHOTREXATE , Cimzia 200 mg solution for injection in pre-filled syringe, LEFLUNOMIDE, RoActemra 162 mg solution for injection in pre-filled syringe., RoActemra 20 mg/mL concentrate for solution for infusion, PREDNISOLONE , Triamcinolone Hexacetonide 20 mg/ml suspension for injection, METHOTREXATE

    The George Institute

    Rheumatoid Arthritis

    approved small molecule active

    1 trial
  7. Humira 40 mg solution for injection in pre-filled pen, ORENCIA 125 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, ORENCIA 250 mg powder for concentrate for solution for infusion, Cosentyx 150 mg solution for injection in pre-filled syringe, Enbrel 25 mg solution for injection in pre-filled syringe, Simponi 45 mg/0.45 mL solution for injection in pre-filled pen., Jylamvo 2 mg/ml oral so

    Istituto Gentili S.r.l.

    Juvenile idiopathic arthritis

    approved small molecule active

    1 trial
  8. IMFINZI 50 mg/mL concentrate for solution for infusion., Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    AstraZeneca

    Advanced or recurrent endometrial cancer

    approved small molecule active

    1 trial
  9. IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., Rixathon 500 mg concentrate for solution for infusion, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, Rixathon 100 mg concentrate for solution for infusion, MTX HEXAL 2,5 mg Tabletten, -, Methotrexat-GRY® 50 mg/2 ml Injektionslösung, ASFOTASE ALFA

    Alexion Europe SAS

    HYPOPHOSPHATASIA

    approved small molecule active

    1 trial
  10. Myozyme 50 mg powder for concentrate for solution for infusion

    Disc Medicine

    Pompe disease / glycogenosis type II / acid maltase deficiency

    approved small molecule active

    1 trial
  11. Myozyme 50 mg powder for concentrate for solution for infusion, Opfolda 65 mg hard capsules, Pombiliti 105 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion

    Disc Medicine

    Pompe disease

    approved small molecule active

    1 trial
  12. Nexviadyme 100 mg powder for concentrate for solution for infusion

    Disc Medicine

    Glycogen storage disease type II or acid maltase deficiency, Pompe disease

    approved small molecule active

    1 trial
  13. Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion

    Sanofi Winthrop Industrie

    Glycogen storage disease type II

    approved small molecule active

    1 trial
  14. OPDIVO 10 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets

    The George Institute

    Renal carcinoma

    approved small molecule active

    1 trial
  15. Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]

    approved small molecule active

    1 trial
  16. Perineural infusion [continuous peripheral nerve block(s)]

    United Therapeutics Europe Ltd

    Phantom Limb Pain

    approved small molecule completed

    1 trial
  17. Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Prostate cancer

    approved small molecule active

    1 trial
  18. Prednisolone 5mg Soluble Tablets, Certican 0,75 mg tablety, Mycofenolaat mofetil Sandoz 250 mg, capsules, hard, Envarsus 0.75 mg prolonged-release tablets, Simulect 20 mg powder and solvent for solution for injection or infusion, Ciclosporine Teva 25 mg, zachte capsules

    Disc Medicine

    kidney transplant

    approved small molecule active

    1 trial
  19. Prednisona Pensa 5 mg comprimidos EFG, Simulect 20 mg powder for solution for injection or infusion, tacrolimus cinfa 1 mg cápsulas duras EFG, Micofenolato Mofetile Accord 250 mg capsule rigide, Metilprednisolona NORMON 40 mg polvo y disolvente para solución inyectable EFG, TIMOGLOBULINA 5 mg/ml, polvo para solución para perfusión

    The George Institute

    Kidney Transplant

    approved small molecule active

    1 trial
  20. RINVOQ 45 mg prolonged-release tablets, Placebo to Match Blinded Upadacitinib, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Chron's Disease

    approved small molecule active

    1 trial
  21. ROCTAVIAN 2 × 1013 vector genomes/mL solution for infusion

    BioMarin Pharmaceutical Australia Pty Ltd

    Hemophilia A

    approved small molecule active

    1 trial
  22. Remsima 100 mg powder for concentrate for solution for infusion

    Disc Medicine

    Crohn's Disease

    approved small molecule active

    1 trial
  23. Sodium Chloride Fresenius Kabi Italia 0,9 % Solution for infusion, MabThera 500 mg concentrate for solution for infusion

    Disc Medicine

    Systemic sclerosis

    approved small molecule active

    1 trial
  24. Sodium Chloride Fresenius Kabi Italia 0.9 % Solution for infusion , DENOSUMAB, Sodium Fluoride (18F) Life Radiopharma 0,1 - 4 GBq/ml solution injectable

    Disc Medicine

    Fibrous dysplasia/McCune-Albright syndrome

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources